| Literature DB >> 11718431 |
Abstract
Chronic myelogenous leukemia (CML) can usually be cured by bone marrow transplantation from matched donors. Donor T-cell activity from the graft is critical to maintaining remission. Myeloablation may not be necessary for cure. Non-myeloablative but immunosuppressive preparative regimens allow donor engraftment with less toxicity. Early combination therapy with interferon-alfa and cytarabine was the preferred option for patients who could not undergo bone marrow transplantation. Now, the advent of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, promises to change existing treatment paradigmsEntities:
Mesh:
Substances:
Year: 2001 PMID: 11718431 DOI: 10.3949/ccjm.68.11.913
Source DB: PubMed Journal: Cleve Clin J Med ISSN: 0891-1150 Impact factor: 2.321